Anand Brahmandam MD , Rafael Alves BM , Hao Liu (刘灏) MD , Luis Gonzalez PhD , Yukihiko Aoyagi (青栁 幸彦) MD , Yuichi Ohashi (大橋 雄一) MD , John T. Langford MD , Carly Thaxton MD , Ryosuke Taniguchi (谷口 良輔) MD, PhD , Weichang Zhang (张惟常) MD, PhD , Hualong Bai (白华龙) MD, PhD , Bogdan Yatsula PhD , Alan Dardik MD, PhD
{"title":"中心动静脉瘘可降低小鼠模型的全身性高血压","authors":"Anand Brahmandam MD , Rafael Alves BM , Hao Liu (刘灏) MD , Luis Gonzalez PhD , Yukihiko Aoyagi (青栁 幸彦) MD , Yuichi Ohashi (大橋 雄一) MD , John T. Langford MD , Carly Thaxton MD , Ryosuke Taniguchi (谷口 良輔) MD, PhD , Weichang Zhang (张惟常) MD, PhD , Hualong Bai (白华龙) MD, PhD , Bogdan Yatsula PhD , Alan Dardik MD, PhD","doi":"10.1016/j.jvssci.2024.100191","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>A central arteriovenous fistula (AVF) has been proposed as a potential novel solution to treat patients with refractory hypertension. We hypothesized that venous remodeling after AVF creation in the hypertensive environment reduces systemic blood pressure but results in increased AVF wall thickness compared with remodeling in the normotensive environment.</p></div><div><h3>Methods</h3><p>A central AVF was performed in C57BL6/J mice previously made hypertensive with angiotensin II (Ang II); mice were sacrificed on postoperative day 7 or 21.</p></div><div><h3>Results</h3><p>In mice treated with Ang II alone, the mean systolic blood pressure increased from 90 ± 5 mmHg to 160 ± 5 mmHg at day 21; however, in mice treated with both Ang II and an AVF, the blood pressure decreased with creation of an AVF. There were significantly more PCNA-positive cells, SM22α/PCNA-positive cells, collagen I deposition, and increased Krüppel-like Factor 2 immunoreactivity in hypertensive mice with an AVF compared with normotensive mice with an AVF.</p></div><div><h3>Conclusions</h3><p>These data show that a central AVF decreases systemic hypertension as well as induces local alterations in venous remodeling.</p></div>","PeriodicalId":74035,"journal":{"name":"JVS-vascular science","volume":"5 ","pages":"Article 100191"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666350324000026/pdfft?md5=60786e70b011585e96e3a0ee22d68666&pid=1-s2.0-S2666350324000026-main.pdf","citationCount":"0","resultStr":"{\"title\":\"A central arteriovenous fistula reduces systemic hypertension in a mouse model\",\"authors\":\"Anand Brahmandam MD , Rafael Alves BM , Hao Liu (刘灏) MD , Luis Gonzalez PhD , Yukihiko Aoyagi (青栁 幸彦) MD , Yuichi Ohashi (大橋 雄一) MD , John T. Langford MD , Carly Thaxton MD , Ryosuke Taniguchi (谷口 良輔) MD, PhD , Weichang Zhang (张惟常) MD, PhD , Hualong Bai (白华龙) MD, PhD , Bogdan Yatsula PhD , Alan Dardik MD, PhD\",\"doi\":\"10.1016/j.jvssci.2024.100191\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>A central arteriovenous fistula (AVF) has been proposed as a potential novel solution to treat patients with refractory hypertension. We hypothesized that venous remodeling after AVF creation in the hypertensive environment reduces systemic blood pressure but results in increased AVF wall thickness compared with remodeling in the normotensive environment.</p></div><div><h3>Methods</h3><p>A central AVF was performed in C57BL6/J mice previously made hypertensive with angiotensin II (Ang II); mice were sacrificed on postoperative day 7 or 21.</p></div><div><h3>Results</h3><p>In mice treated with Ang II alone, the mean systolic blood pressure increased from 90 ± 5 mmHg to 160 ± 5 mmHg at day 21; however, in mice treated with both Ang II and an AVF, the blood pressure decreased with creation of an AVF. There were significantly more PCNA-positive cells, SM22α/PCNA-positive cells, collagen I deposition, and increased Krüppel-like Factor 2 immunoreactivity in hypertensive mice with an AVF compared with normotensive mice with an AVF.</p></div><div><h3>Conclusions</h3><p>These data show that a central AVF decreases systemic hypertension as well as induces local alterations in venous remodeling.</p></div>\",\"PeriodicalId\":74035,\"journal\":{\"name\":\"JVS-vascular science\",\"volume\":\"5 \",\"pages\":\"Article 100191\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666350324000026/pdfft?md5=60786e70b011585e96e3a0ee22d68666&pid=1-s2.0-S2666350324000026-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JVS-vascular science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666350324000026\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JVS-vascular science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666350324000026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
A central arteriovenous fistula reduces systemic hypertension in a mouse model
Objective
A central arteriovenous fistula (AVF) has been proposed as a potential novel solution to treat patients with refractory hypertension. We hypothesized that venous remodeling after AVF creation in the hypertensive environment reduces systemic blood pressure but results in increased AVF wall thickness compared with remodeling in the normotensive environment.
Methods
A central AVF was performed in C57BL6/J mice previously made hypertensive with angiotensin II (Ang II); mice were sacrificed on postoperative day 7 or 21.
Results
In mice treated with Ang II alone, the mean systolic blood pressure increased from 90 ± 5 mmHg to 160 ± 5 mmHg at day 21; however, in mice treated with both Ang II and an AVF, the blood pressure decreased with creation of an AVF. There were significantly more PCNA-positive cells, SM22α/PCNA-positive cells, collagen I deposition, and increased Krüppel-like Factor 2 immunoreactivity in hypertensive mice with an AVF compared with normotensive mice with an AVF.
Conclusions
These data show that a central AVF decreases systemic hypertension as well as induces local alterations in venous remodeling.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
